Presented by Dr. Harry Quon & Dr. Mike Passineau
Monday, August 18th at 7pm ET (4pm PT)
Webinar Description: Join us for a compelling TAD Talk, No Spit Sherlock: Cracking the Case of Dry Mouth After Cancer, featuring Drs. Harry Quon and Mike Passineau. This session will provide a deeper understanding of xerostomia—commonly known as dry mouth—and its significant impact on quality of life for patients following radiation treatment for head and neck cancer. Attendees will gain insight into groundbreaking research on gene therapy targeting salivary glands, including key findings from a completed Phase 1 clinical trial. The webinar will also highlight the objectives and progress of a Phase 2 clinical study aimed at improving xerostomia outcomes for head and neck cancer survivors.
Length: 1 Hour
Target Audience: Speech-language pathologists, oncologists, otolaryngologists, dentists, and other healthcare providers specializing in dysphagia and head and neck cancer.
Learner Objectives:
1. Explore the goals and current progress of an ongoing Phase 2 clinical study focused on improving xerostomia in head and neck cancer survivors.
2. Gain a deeper understanding of xerostomia and its effects on patients following radiation treatment for head and neck cancer.
3. Learn about the use of gene therapy in salivary glands, including findings from a completed Phase 1 clinical trial for radiation-induced xerostomia.
ASHA CEUs: .1 ASHA CEUs will be offered for this free webinar. To receive ASHA CEUs, participants must attend full broadcast and complete post-webinar survey within 7 days. ASHA CEUs are provided by ASHA CE provider, STEP Community.
Note: This webinar will not be recorded. ASHA CEUs are only provided for the live broadcast.
Meet the Presenters
Harry Quon, MD, MS
Dr. Harry Quon is an associate professor of radiation oncology and molecular radiation sciences at the Johns Hopkins University School of Medicine. He also holds appointments in oncology and in otolaryngology – head and neck surgery. His area of clinical expertise is radiation treatment for head and neck cancers. He serves as the co-director of the Johns Hopkins Head and Neck Cancer Multidisciplinary Clinic. Dr. Quon received his M.D. from the University of Toronto Institute of Medical Science. He completed his residency at the Princess Margaret Hospital in Ontario and performed a fellowship in radiation oncology at the Princess Margaret Hospital and the Beth Israel Medical Center.
Mike Passineau, PhD
Dr. Mike Passineau currently serves as Vice President and Head of Salivary Gland Therapeutics at MeiraGTx (NASDAQ: MGTX), a global gene therapy company headquartered in New York City with primary manufacturing facilities in London and Shannon, Ireland. Since 2021, he has led clinical drug development and research for the company’s lead therapeutic candidate, AAV2-hAQP1—a gene therapy designed to treat radiation-induced xerostomia and Sjögren’s disease. This candidate successfully completed a Phase 1 clinical trial in March 2023, with Phase 2 trials initiated in June 2023. Before joining MeiraGTx, Dr. Passineau spent 13 years at Allegheny Health Network and Drexel University College of Medicine in Pittsburgh, where he retired as a full professor in 2021. He holds a BA in Chemistry and Bible from Cedarville University, a PhD in Neuroscience from the University of Miami, and completed a postdoctoral fellowship at the University of Alabama at Birmingham.
Cost: FREE. This webinar has been made free to all registrants thanks to a generous unrestricted educational grant provided by Bracco Diagnostics and the educational sponsors of the NFOSD.
NFOSD Educational Sponsors
